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Abstract: Type 2 diabetes (T2D) is a metabolic disorder where insulin-sensitive tissues show reduced
sensitivity towards insulin and a decreased glucose uptake (GU), which leads to hyperglycaemia.
Peroxisome proliferator-activated receptor (PPAR)γ plays an important role in lipid and glucose
homeostasis and is one of the targets in the discovery of drugs against T2D. Activation of PPARγ by
agonists leads to a conformational change in the ligand-binding domain, a process that alters the
transcription of several target genes involved in glucose and lipid metabolism. Depending on the
ligands, they can induce different sets of genes that depends of their recruitment of coactivators.
The activation of PPARγ by full agonists such as the thiazolidinediones leads to improved
insulin sensitivity but also to severe side effects probably due to their behavior as full agonists.
Partial PPARγ agonists are compounds with diminished agonist efficacy compared to full agonist
that may exhibit the same antidiabetic effect as full agonists without inducing the same magnitude
of side effects. In this review, we describe a screening platform for the identification of partial
PPARγ agonists from plant extracts that could be promising lead compounds for the development
of antidiabetic drugs. The screening platform includes a series of in vitro bioassays, such as GU in
adipocytes, PPARγ-mediated transactivation, adipocyte differentiation and gene expression as well
as in silico docking for partial PPARγ agonism.
Keywords: type 2 diabetes; screening platform; partial PPARγ agonists; adipocytes; insulin;
glucose uptake; PPARγ transactivation; adipocyte differentiation; in silico; plant extracts.
1. Introduction
In 2015, it was estimated that more than 415 million adults globally had diabetes mellitus, of which
over 90% suffered from type 2 diabetes (T2D), and this number is projected to rise to around 642 million
by 2040 [1]. Insulin resistance plays an essential role in the development of T2D, and is characterized
by glucose intolerance resulting in elevated fasting glucose. Insulin resistance is mediated by high
circulating levels of free fatty acids and by the release of certain hormones and inflammatory cytokines
from adipose tissue, which impair insulin signaling in insulin sensitive tissues [2,3]. The hormones
adiponectin and leptin are, however, important metabolic regulators that are crucial for maintaining
a normal level of insulin sensitivity. Adiponectin increases the catabolism of free fatty acids and
leptin increases energy expenditure leading to a reduction in insulin resistance. Insulin resistance is
the prediabetic state where insulin sensitive tissues such as muscles and fat show reduced insulin
sensitivity and a decrease in glucose uptake (GU). The prediabetic state is initially counteracted by an
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increased release of insulin from pancreatic β-cells to maintain glucose homeostasis. Eventually, the
β-cells fail to sustain a sufficient insulin production resulting in hyperglycemia and T2D [2,3].
Patients suffering from T2D are treated with life-style changes including exercise and
diet restriction, insulin and/or oral anti-hyperglycemic drugs. Anti-hyperglycemic drugs
such as sulfonylureas and meglitinides (e.g., repaglinide) increase insulin secretion, biguanides
(e.g., metformin) increase insulin sensitivity (insulin sensitizers), α-glucosidase inhibitors (e.g.,
acarbose and miglitol) work by preventing the digestion of starch and other carbohydrates in the small
intestine and the thiazolidinediones (TZDs) such as rosiglitazone (Rosi) and pioglitazone are efficient
insulin-sensitizing drugs [4–7]. TZDs act by activating peroxisome proliferator-activated receptor
(PPAR)γ [6,7], which belong to a group of nuclear receptor proteins of ligand-inducible transcription
factors regulating the expression of many genes. In mammals, there are beside PPARγ also PPARα
and PPARβ/δ. PPARs consist of distinct functional domains including an N-terminal transactivation
domain, a highly conserved DNA-binding domain (DBD), and a C-terminal ligand-binding domain
(LBD) that contains a ligand-dependent transactivation function. The DBD anchors the PPARs to their
binding sites on the DNA template. PPARs form obligate heterodimers with retinoid X receptor (RXR),
which then binds to specific regions on the DNA of target genes. These specific DNA regions are termed
PPAR response elements (PPREs). In the absence of a ligand, high-affinity complexes are formed
between the inactive PPAR/RXR heterodimers and corepressor molecules. Upon ligand binding to
the PPAR/RXR heterodimer, a conformational change in the LBD leads to release of the corepressor
and binding of a coactivator resulting in expression of the target gene. PPARs control the expression
of networks of genes involved in adipogenesis, lipid metabolism, inflammation, and maintenance of
metabolic homeostasis [8–13]. PPARα, is expressed in kidneys, liver, heart and skeletal muscles as well
as adipose tissue, where it is a major activator of fatty acid oxidation pathways and is the target of
hypolipidemic drugs [12,14–16]. PPARβ/δ shares similar functions with PPARα, and is ubiquitously
expressed and has a key role in fatty acid oxidation in skeletal muscle, liver and heart, and appears to be
an important regulator of energy expenditure, and glucose and lipid metabolism [14–16]. PPARγ exists
in two isoforms PPARγ1 and PPARγ2. PPARγ1 is expressed in several tissues, including the lower
intestines, macrophages, and adipose tissue, whereas PPARγ2 is predominantly expressed in adipose
tissue. The latter is the isoform of PPARγ, which is the focus of this review.
PPARγ is involved in many physiological processes and in particularly in the regulation of
insulin sensitivity, inflammation, fatty acid storage, and glucose metabolism; hence, PPARγ represents
an interesting pharmacological target being able to alleviate several of the underlying pathologies
of T2D [6,9,10,12,13,15]. Activation of PPARγ leads to differential recruitment of coactivators and
subsequent modulation of PPARγ activity. This process alters the transcription of several target
genes involved in carbohydrate and lipid metabolism resulting in for example facilitation of GU
and lipid uptake, decrease in free fatty acid levels and amelioration of insulin resistance [11,17–22].
Common dietary fatty acids such as oleic, linoleic and linolenic acids as well as endogenous prostanoids
and phospholipids are ligands of PPARγ [11,23–25]. Other types of natural products that have been
shown to be agonists of PPARγ are flavonoids, stilbenes, neolignans, amorfrutins, polyacetylenes,
alkamides, sesquiterpene lactones, diterpenoids and triterpenoids [13,26–30]. Synthetic ligands of
PPARγ as for example the TZDs are known to cause severe side effects such as increased water retention,
oedema, weight gain, heart enlargement, and hepatotoxicity [30–34]; consequently, many TZDs drugs
have been withdrawn from the market. The unwanted side effects of TZDs have been associated
with their behavior as full agonists of PPARγ [7,11,30]. By contrast, partial PPARγ agonists are
compounds with diminished agonist efficacy that maintain the insulin-sensitizing effect but usually
without inducing the same magnitude of side effects as observed for full agonists [7,11]. In silico
docking studies have revealed that full and partial agonists have different binding modes in the
LBD of PPARγ [13,18,35–38]. This may explain why full and partial agonists recruit different sets of
coactivators, and exhibits different pharmacological activities [13,18,39]. The search for PPARγ ligands
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with improved mechanisms of action is therefore an important objective to discover new promising
antidiabetic compounds.
Plants have been used for centuries in the treatment of diabetes and are considered as a source
for antidiabetic natural products [40–43]. The aim of this review is to introduce an in vitro screening
platform for the identification of potential antidiabetic partial PPARγ agonists from complex plant
extracts. The screening platform has for example been used to identify promising antidiabetic
alkamides and polyacetylenes from purple coneflower (Echinacea purpurea (L.) Moench, Asteraceae)
and carrots (Daucus carota L., Apiaceae), respectively, and how this has been done will be described.
2. Screening Platform
The screening platform consists of several different bioassays as well as in silico docking for
verification of partial PPARγ agonism, with the experimental strategy outlined in Figure 1.
Figure 1. Screening platform for the identification of partial PPARγ agonists with potential antidiabetic
properties. The most essential part of the screening platform is indicated in the dotted area.
The first step consist of a bioassay, which tests extracts, fractions and/or purified natural products
(≈ test sample) for insulin-dependent GU in adipocytes. If a significant effect on GU is observed then
testing is continued, otherwise it is stopped. In the next step, the ability of the test sample to activate
PPARγ compared to a positive control (e.g., Rosi) is determined. In addition, the adipogenic potential
of the test sample is determined in an adipocyte differentiation bioassay. If the test sample shows
significantly lower activation of PPARγ and no significant stimulation of adipocyte differentiation
compared to the positive control, then the test sample demonstrates promising antidiabetic effect
that may be due to partial PPARγ agonism, and testing continues (Figure 1). Expression of genes
involved in adipogenesis, lipogenesis, lipolysis, transportation and absorption of glucose may provide
important information about the mechanisms of action of a test sample. If the test sample is a natural
product with a known chemical structure, its partial PPARγ activity is investigated by in silico docking.
A test sample that passes through all steps in the platform may contain natural products that may
be antidiabetic lead compounds (Figure 1). In Figure 1, additional tests are also indicated, such as
coactivator recruitment assays, testing for PPARα and PPAR β/δ transactivation as well as preclinical
studies in rodents. PPARγ agonists that activate PPARα or PPARβ/δ are dual agonists. Agonists acting
on all three PPAR receptors are pan agonists. Activation of PPARα and/or PPAR β/δ may result in
the improvement of lipid profile, reduced adiposity and insulin sensitivity [44,45]. These additional
tests are important to elucidate the overall activity profile of a promising antidiabetic lead compound,
but will not be discussed in this review.
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Extracts from numerous medicinal and food plants have been investigated for their potential
antidiabetic effects [13,40,41,46]. For example, it has been shown that lipophilic extracts of roots
of E. purpurea and carrots have promising antidiabetic effects, although these plants have not been
used in traditional medicine for the treatment of diabetes. We have together with colleagues recently
used the screening platform to characterize the potential antidiabetic compounds from these plant
species [47,48], and this will be described in the following sections.
3. Insulin-Dependent and Basal GU
Insulin plays an essential role in glucose homeostasis by increasing storage or utilization
of glucose by regulating the transport of glucose into the cell. Glucose transport into cells
is catalyzed by several transport protein isoforms of which glucose transporter type 4 (Glut4),
specifically facilitate glucose transport into insulin-sensitive tissue. Glut4 is insulin-dependent,
and plays a key role in GU. In non-stimulated cells, the majority of Glut4 is found within intracellular
storage vesicles. Upon stimulation by insulin, Glut4 redistributes and is incorporated into the
plasma membrane of the cell where it mediates GU. Thus, insulin increases GU by increasing the
concentration of Glut4 at the plasma membrane rather than enhancing the intrinsic activity of this
transporter [49–52]. PPARγ activation by TZDs has been shown to increase the expression and
translocation of Glut4 as well as the insulin-independent transporter type 1 (Glut1) to the cell surface.
Consequently, PPARγ activation promote insulin-dependent and basal GU in adipocytes and muscle
cells by upregulating gene expression for glucose transporters [31,53,54].
T2D is associated with a state of chronic inflammation in adipose tissue that secrete
elevated levels of proinflammatory cytokines (e.g., TNFα, interleukin-6, and resistin), which all
promotes insulin resistance [10,16,55–57]. Agonists of PPARγ have been shown to inhibit the
expression of proinflammatory cytokines and to increase the plasma concentrations of the hormone
adiponectin [10,16,30,58,59]. Adiponectin is positively associated with insulin sensitivity through
increased fatty acid oxidation and inhibition of hepatic glucose production [59,60]. Adiponectin is
present in relative high concentrations in plasma, but lower in obese subjects compared to lean
subjects [61,62]. Reduced levels of adiponectin are in particular found in patients diagnosed with
T2D [59,62]. A significant increase in insulin-dependent GU in adipocytes of a test sample is strong
evidence that it contains compound(s) that positively affect insulin trafficking.
3.1. Identification of Potential Antidiabetic Compounds from Plants with Effect on Insulin-Dependent GU
To study insulin-dependent GU in adipocytes two approaches can be used. Firstly, one can
investigate the effect at different concentrations at a fixed insulin concentration, which is usually 10 nM
insulin corresponding to the insulin concentration in human healthy subjects. The concentration is
normally in the range between 1–100 µg/mL for extracts or fractions, and for pure natural products
from 0.1–30 µM to avoid cytotoxic effects and because higher concentrations indicates too low
antidiabetic efficacy. Another approach is to investigate insulin-dependent GU at a fixed concentration,
which is typically between 1–100 µg/mL for extracts/fractions and from 0.1–30 µM for pure natural
products, at different insulin concentrations (e.g., at 3, 10, 30 and 100 nM) or with no insulin to
determine basal GU [47,48].
3.1.1. Alkamides in the Roots of E. purpurea Show an Effect on Insulin-Dependent GU
In a recent study by Kotowska et al. [47], it was demonstrated that a dichloromethane (DCM)
extract (100 µg/mL) of the roots of E. purpurea increased basal GU 2-fold in mature 3T3-L1
adipocytes compared to the vehicle (DMSO). Further, the GU was enhanced in the presence of 3
and 10 nM of insulin. These results suggests that this extract contain natural products that increases
insulin sensitivity in 3T3-L1 adipocytes [47]. Separation of the DCM extract by normal-phase
flash column chromatography (flash CC) resulted in nine fractions (A–I). Fractions A and D
increased insulin-dependent GU with the latter being the most active fraction. Investigation of
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the active fractions by high-performance liquid chromatography−diode array detection−tandem
mass spectrometry (HPLC-DAD-MS/MS) revealed that fraction A contained the PPARγ agonist
α-linolenic acid as a major constituent. Fraction D contained an inseparable mixture of the novel
isomeric alkamides dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides in a 1:1 ratio as
shown by NMR spectroscopy [47], as well as the known alkamides dodeca-2E,4E,8Z-trienoic acid
isobutylamide and dodeca-2E,4E-dienoic acid isobutylamide, which were isolated by semi-preparative
HPLC (Figure 2).
Figure 2. Chemical structures of alkamides isolated from an active fraction of a DCM root extract of
Echinacea purpurea that demonstrated significant insulin-dependent GU activity.
The isomeric dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides at 30 µM resulted in
a significant increase in basal GU compared to the vehicle (DMSO) and the positive control Rosi
(Figure 3). These alkamides also significantly stimulated insulin-dependent GU (Figure 3). On the
other hand dodeca-2E,4E,8Z-trienoic acid isobutylamide and dodeca-2E,4E-dienoic acid isobutylamide
showed only a weak increase of basal GU and insulin-dependent GU in mature 3T3-L1 adipocytes at
30 µM [47]. Thus dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides seem to be the main
contributors to the observed potential antidiabetic effect of the DCM extract of E. purpurea roots and
were selected for further studies in the screening platform.
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3.1.2. Polyacetylenes from Carrot Roots Show an Effect on Insulin-Dependent GU
In a study by El-Houri et al. [48], it has recently been shown that the DCM extract of
carrot roots in concentrations between 1–30 µg/mL stimulated insulin-dependent GU in 3T3-L1
adipocytes at 10 nM insulin in a dose dependent manner (Figure 4). Fractionation of the extract by
normal-phase flash CC resulted in 10 fractions (A–J) of which fraction C and F showed significant
stimulation of insulin-dependent GU relative to the vehicle (0.1% DMSO). Fraction C and F increased
insulin-dependent GU in a dose-dependent relationship (Figure 4). Fraction C contained mainly the
polyacetylene (3R)-falcarinol (FaOH) while fraction F contained mainly (3R,8S)-falcarindiol (FaDOH)
as shown by HPLC-DAD-MS/MS and other chemical analysis (Figure 5) [48].
Figure 4. Effect of a DCM extract of carrot roots and active fractions (C and F) on insulin-dependent GU
in mature 3T3-L1 adipocytes at 10 nM insulin, relative to 0.1 % DMSO (vehicle, 100%) and the positive
control Rosi (1 µM). All values are expressed as a mean ± SD of three independent experiments in
triplicates. * p < 0.01, ** p < 0.001, indicate significance relative to the vehicle.
Figure 5. Effect of FaOH and FaDOH on insulin-dependent GU in mature 3T3-L1 adipocytes relative to
0.1% DMSO (vehicle, 100%). Insulin concentration was 10 nM, and the positive control was Rosi (1 µM).
All values are expressed as a mean ± SD of three independent experiments in triplicates. * p < 0.01,
** p < 0.001, indicate significance relative to the vehicle.
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Purified FaOH and FaDOH showed an increased insulin-dependent GU in the concentration
range between 0.3–30 µM with FaDOH being more potent than FaOH at all concentrations tested
(Figure 5).
4. PPARγ Transactivation Assay
Recruitment of coactivators to the PPARγ-RXR complex in response to different ligands leads to
major differences in the transactivation of target genes. Thus, the challenge is to find ligands with an
optimal biological profile, i.e., ligands that recruit coactivators resulting in antidiabetic effects with no
or reduced adverse effects compared to full PPARγ agonists.
Partial PPARγ agonists are compounds that activate PPARγ weaker than full agonists, and in
addition may induce recruitment of beneficial coactivators with regard to controlling glucose
homeostasis, energy expenditure, insulin-dependent GU, and adipogenesis. Numerous coactivators
have been identified and includes the steroid receptor coactivator (SRC) family of coactivators,
PPARγ coactivator-1 (PGC-1) family of coactivators, CBP (CREB binding protein), and TRAP220
of the mediator complex [11,20,55,63–65] of which some coactivators result in beneficial effects and
others in adverse effects [66]. The steroid receptor coactivator-1 (SRC-1) regulates key metabolic
pathways, including glucose homeostasis. Furthermore, SRC-1-deficient mice have been shown
to have reduced energy expenditure and to be susceptible to obesity; thus SRC-1 is a beneficial
coactivator [66–68]. PPARγ coactivator 1-α (PGC-1α) is a key coactivator for regulating glucose
metabolism and whole body energy expenditure and is also a beneficial coactivator [66,69]. On the
other hand, the TRAP220 coactivator of the mediator complex has been shown to interact with
PPARγ and to stimulate adipogenesis, resulting in expression of genes associated with lipid storage
and weight gain [70]. The coactivator transcriptional mediator/intermediary factor 2 (TIF2)/SRC-2
also promotes fat accumulation in adipocytes [67] and therefore TRAP220 and TIF2 are considered as
adverse coactivators. Finally, PPARγ agonists may also recruit repressors and an example of such a
ligand-dependent transcriptional repressor is receptor interacting protein (RIP) 140, which represses
genes involved in energy expenditure [71]. A desired partial PPARγ agonist profile should therefore
result in recruitment of coactivators that improves glucose metabolism and energy expenditure and
not induce adipogenesis. A test sample that in the screening platform significantly improves insulin-
stimulated GU and exhibit significantly less activation of PPARγ compared to TZDs, indicates that it
possess the characteristics of a partial PPARγ agonist recruiting beneficial coactivators.
4.1. Identification of Potential Partial PPARγ Agonists from Plants
Plant extracts have high hit rates when tested for PPARγ activity [40,41,46], because they often
contain common PPARγ activators such as polyunsaturated fatty acids. Consequently, PPARγ activity
assays cannot stand alone in the search for promising antidiabetic natural products but need to be
supported by additional information (Figure 1). PPARγ ligand activity of a test sample is usually
determined using a PPARγ transactivation bioassay such as a luciferase reporter gene cell-based assay.
In case of pure compounds, a competitive PPARγ receptor-binding assay in agonist mode using a
time-resolved fluorescence resonance energy transfer (TR-FRET) assay with purified PPARγ protein is
also often used in combination with the PPARγ transactivation bioassay [13]. The binding assay with a
receptor protein is one of the most direct approaches to confirm a potential binding and/or interaction
of a ligand with PPARγ. Application of a receptor-binding assay is, however, not sufficient to guarantee
that a compound can act also in cells in vivo, due to its inability to penetrate cellular membranes,
transportation out of cells mediated by membrane efflux transporters or metabolic transformation
to products that are not PPARγ ligands [13]. PPARγ transactivation bioassays may compensate for
the pitfalls in the receptor-binding assay but these cellular models then have other disadvantages.
For example, PPARγ activation determined in a luciferase reporter cell-based assay might be the result
of indirect effects such as increase in PPARγ protein expression, activation of RXR etc. [13]. Despite the
different weaknesses of the methods for the determination of PPARγ activity, they are relatively fast
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and provide important information on whether a compound is as a partial or full PPARγ agonist or an
extract/fraction contains promising PPARγ activators.
4.1.1. PPARγ Activity of Alkamides from E. purpurea
Dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides were shown to significantly activate
PPARγ at a concentration of 30 µM compared to the vehicle DMSO, but the effect was weak compared
to Rosi [47]. Furthermore, dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides and Rosi
were shown to compete with a fluorescent pan PPAR agonist in a ligand binding assay indicating a
common binding site in the PPARγ LBD [47]. The results indicates that these alkamides are partial
PPARγ agonists, which was confirmed by in silico docking (see Section 6.1).
4.1.2. PPARγ Activity of FaOH and FaDOH from Carrots
FaDOH was shown to significantly activate PPARγ 3-fold, at the highest tested concentration
(30 µM) compared to the vehicle (0.1% DMSO) in a PPARγ transactivation bioassay. FaOH showed
a weak but significant 1.6-fold activation of PPARγ at 10 µM, but not at 3 µM and 30 µM.
PPARγ activation of FaOH and FaDOH was significant lower compared to the positive control
Rosi [48]. The results indicates that FaOH and FaDOH are partial PPARγ agonists, which was
confirmed by in silico docking studies (see Section 6.1). For FaDOH, this is in accordance with a
study of Atanasov et al. [72] who showed that FaDOH binds to purified human PPARγ and activates
PPARγ-dependent reporter gene expression as a partial agonist between 1–30 µM, and antagonizes
the effect of Rosi.
5. Adipocyte Differentiation
PPARγ play a key role in the regulation of lipid storage and control of fatty acid metabolism
and is considered a master regulator of adipocyte differentiation [9,64,73,74]. Another transcription
factor that is strongly involved in adipogenesis is cytidine-cytidine-adenosine-adenosine-thymidine
(CCAAT)/enhancer-binding protein α (C/EBPα). However, it is unclear how PPARγ and C/EBPα
function cooperatively during the adipocyte differentiation process. An important protein involved
in adipogenesis is adipocyte protein 2 (aP2), which is a key mediator of intracellular transport and
metabolism of fatty acids. aP2 gene is highly expressed in adipocytes and macrophages and plays an
important role in the development of insulin resistance and atherosclerosis. The expression of aP2 is
highly regulated during adipocyte differentiation by PPARγ and C/EBPα [75,76]. Stearoyl-coenzyme
A desaturase (SCD1) is a key enzyme in the control of lipid metabolism and is rate limiting for
the conversion of saturated fatty acids to monounsaturated fatty acids and thus the formation
of triglycerides and other lipids. SCD1 gene is highly expressed in adipose tissue [77,78].
PPARγ upregulation of SCD1 leads to increased lipogenesis and elevated levels of SCD1 is associated
with obesity. This is also in accordance with the fact that SCD1-deficient or knockout mice are protected
from obesity and show increased insulin sensitivity [79,80]. Therefore, overexpression of SCD1 in
humans may be involved in the development of T2D, hypertriglyceridemia, and atherosclerosis.
Adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) are the major key enzymes
involved in the breakdown of triglycerides to fatty acid derivatives and their activity are regulated
by insulin. The free fatty acid derivatives released during lipolysis can serve as intrinsic ligands for
PPARγ and can impair insulin-signaling [81,82]; hence, the regulation of ATGL and HSL are important
in relation to obesity, T2D, and related metabolic disorders.
5.1. Adipocyte Differentiation Bioassays and Gene Expression
PPARγ play a central role in the differentiation of preadipocytes into mature adipocytes.
The process of cell differentiation by which preadipocytes become adipocytes is complex and
involves genes, which are a part of the insulin-signaling cascade, thereby improving insulin
sensitivity [83]. The critical window for ligand-dependent induction of adipocyte differentiation
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of 3T3-L1 cells is days 0 to 4 after induction of differentiation. To induce differentiation of
3T3-L1 preadipocytes into mature adipocytes, a cocktail consisting of the synthetic glucocorticoid
dexamethasone, 1-methyl-3-isobutylxanthine, and insulin (MDI protocol) is often used [40,41,47,48,84].
PPARγ stimulates the production of small insulin-sensitive adipocytes but also plays an important
role in regulating lipid metabolism in mature adipocytes by increasing fatty acid trapping and
storage of lipids in adipose tissue. This results in lowering of circulating free fatty acids in liver
and muscles as well as modifying secretion of hormones from adipose tissue, all factors known to
improve insulin sensitivity. The insulin sensitizing effects of full PPARγ agonist are linked to their
ability to increase adipogenesis and to shift the energy balance toward storage and redistribution
of fat from visceral to subcutaneous adipose tissue as well as to increase the population of small
adipocytes and simultaneously decrease the population of large adipocytes [8,11,15,30]. This may
explain the insulin-sensitizing effects of TZDs but also one of their major side effects, which is increase
in whole-body adiposity (weight gain). Thus, in the search for potential antidiabetic natural products
that activate PPARγ, it is essential that they do not significantly stimulate adipocyte differentiation
and fat accumulation.
The adipogenic potential of a test sample, in this screening platform is determined in
preadipocytes and/or in mature adipocytes using the MDI protocol and Oil Red O to stain the
triglycerides. Together with gene expression studies in preadipocyes and mature adipocytes, it gives
useful information of potential antidiabetic effects of a test sample [27,28,40,41,47,48]. With regard
to fat accumulation, the worm Caenorhabditis elegans has been shown to serve as an excellent in vivo
model for fast screening for fat accumulation, which can provide useful information about energy
homeostasis and fat storage pathways in a whole organism [40,85]. However, this in vivo model is not
an essential part of the screening platform and will not be discussed in this review.
5.2. Investigation of Adipocyte Differentiation of Dodeca-2E,4E,8Z,10E/Z-Tetraenoic Acid 2-Methyl-butylamides
Kotowska et al. [47] investigated the effect of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid
2-methylbutylamides on adipogenesis, glucose transport, lipogenesis, and adipokines in the early
stages of adipocyte differentiation in mature 3T3-L1 cells treated with 30 µM of the alkamides.
Dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides were shown to increase the gene
expression of key markers for adipogenesis (PPARγ, aP2, C/EBPα) as well as adiponectin and Glut1,
whereas the gene expression for Glut4 and SCD1 was significantly downregulated (Figure 6).
Figure 6. Effect of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides (30 µM) on gene
expression of proteins involved in adipogenesis (PPARγ, C/EBPα, aP2), glucose transport (Glut1,
Glut4), lipogenesis (SCD1), and adipokines (adiponectin) in mature 3T3-L1 cells. Rosi (1 µM) was the
positive control. All values are normalized to the vehicle DMSO and are expressed as a mean ± SD of
three independent experiments in triplicates. ** p < 0.001 indicates significance relative to DMSO.
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The downregulation of SCD1 gene expression may result in decreased lipogenesis and a small size
of lipid droplets [86]. Glut1 is expressed in both preadipocytes and mature adipocytes, whereas Glut4 is
expressed only in mature adipocytes. The upregulation of Glut1 gene expression is in accordance with
the enhanced basal GU observed for dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides,
whereas the observed effect on insulin-dependent GU of these alkamides (Figure 3) appears not to be
related to the gene expression of glucose transporters [47]. Adiponectin also plays an important role in
mediating GU in adipocytes and was significantly upregulated by dodeca-2E,4E,8Z,10E/Z-tetraenoic
acid 2-methylbutylamides, which suggests that the adipocytes might be insulin sensitive [87] in
accordance with their effect on insulin-dependent GU.
5.3. Investigation of Adipocyte Differentiation of FaOH and FaDOH
FaOH impair adipocyte differentiation as shown in 3T3-L1 preadipocytes whereas this is not
the case for FaDOH (Figure 7) [48]. The impairment of adipocyte differentiation by FaOH may
reflect competition between endogenous activators of PPARγ needed for induction of adipocyte
differentiation in combination with the weak activation of PPARγ by FaOH.
Figure 7. Effect of FaOH (30 µM), FaDOH (30 µM), vehicle (0.1% DMSO) and Rosi (1 µM), respectively,
on adipocyte differentiation (MDI protocol) in 3T3-L1 preadipocyte. Cells were stained with Oil Red O
on day 8.
El-Houri et al. [48] observed no upregulation of the key markers of adipogenesis (PPARγ, C/EBPα)
for FaOH and FaDOH (Figure 8). However, a significant upregulation of the gene expression of
aP2 was found in response to treatment with FaDOH, whereas FaOH was found not to have an
effect on aP2 gene expression (Figure 8). These results are in accordance with the impairment of
adipocyte differentiation observed for FaOH and both polyacetylenes being weak activators of PPARγ.
The significant upregulation of aP2 by FaDOH clearly indicates that it is more potent with regard to
a potential antidiabetic effect and has a higher efficacy in relation to PPARγ activation than FaOH.
This is also in accordance with other investigations of this type of polyacetylenes [13,72].
FaOH and FaDOH did not affect SCD1 gene expression significantly in accordance with the
results from the adipocyte differentiation assay (Figure 7). However, a significant upregulation of the
gene expression of ATGL and HSL was observed for FaDOH (Figure 8). Expression of these genes
has been shown to contribute to the increase of plasma fatty acids that affect insulin sensitivity [88].
In contrast, FaOH significantly downregulated the expression of the HSL gene and had no significant
effect on ATGL gene expression (Figure 8).
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Figure 8. Effect of FaOH and FaDOH on gene expression of key proteins involved in adipogenesis
(PPARγ, C/EBPα, aP2), lipogenesis (SCD1), lipolysis (ATGL, HSL) and the adipokine adiponectin
in mature 3T3-L1 cells. Rosi was the positive control. All values are normalized to the vehicle 0.1%
DMSO and are expressed as a mean ± SD of three independent experiments in triplicates. ** p < 0.001
indicates significance relative to 0.1% DMSO.
The differences between FaOH and FaDOH on expression of ATGL and HSL as well as on
adipocyte differentiation, indicates that these polyacetylenes have distinct mechanisms of action in
adipocytes. This was supported by in silico docking studies that showed that FaOH and FaDOH had
different affinities to the PPARγ LBD (see Section 6.1). Thus, it could be interesting to investigate
the effect of FaOH and FaDOH on a wider range of transcription factors involved in adipogenesis,
recruitment of PPARγ coactivators, and glucose transporters in order to elucidate their possible
mechanisms of action and evaluate their potential antidiabetic effects in preclinical trials.
6. In Silico Screening for Identification of PPARγ Agonists
In silico screening is an important technique for selecting promising antidiabetic compounds for
experimental testing in vitro and in vivo as well as to verify and understand the binding modes of
ligands towards nuclear receptors. Docking and structure-based 3D pharmacophores are the most used
approaches within in silico screening. Docking is used to investigate the binding modes of a ligand at a
protein-binding site whereas structure-based 3D pharmacophores describe protein-ligand interactions
by various chemical features that can then be used for virtual screening [18,37,38]. Different docking
methods exist and structural details for the binding of an agonist to the PPARγ LBD are available for
over 100 receptor-ligand crystal structures of which several have been solved for different natural
products [18]. Investigation of these crystallographic structures have revealed two specific binding
modes in the PPARγ LBD, which correspond to full and partial agonists, respectively.
The LBD consists of 13 α-helices labelled H1–H12 and H2’, as well as one β-sheet region.
The ligand-binding pocket of PPARγ LBD is located in the centre of the LBD and is a large Y-shaped
ligand-binding cavity, consisting of three binding pockets (arm I–III) of which each pocket have
different properties and binding preferences. Arm III is the entrance arm that branches off into arm I
and arm II. Arm I is extended toward H12 of the ligand-dependent activation domain whereas arm II is
situated between H3 and the β-sheet. Arm I is the polar cavity of the PPARγ LBD, whereas arm II and
the interior of arm III are mainly hydrophobic [11,13,18]. Full agonists occupy arm I and form hydrogen
bonds with the amino acids Ser289, His323, His449, and Tyr473. These interactions stabilize H12 and are
mainly responsible for the PPARγ activity of full agonists. In addition, full agonists also interact with
arm II through a hydrophobic tail but these interactions appears to be of minor importance in relation
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to the transactivation activity of PPARγ [11,13,18]. Partial agonists interact mainly with amino acids in
arm III forming a hydrogen bond to Ser342, but interact also with arm II through several hydrophobic
interactions [11,13,18,47,48]. This binding mode of partial PPARγ agonists causes a lower degree of H12
stabilization and an increase in the stabilization of H3, which affects the recruitment of coactivators and
decreases the transactivation activity of PPARγ. This explains why the PPARγ transactivation activity
is lower for partial agonists compared to full agonists but does not explain why agonists with different
PPARγ transactivation activities may have similar insulin-sensitizing activities. The antidiabetic
efficacy of different ligands does not only correlate with the ligand-binding affinity but also their
ability to inhibit phosphorylation of PPARγ by cyclin-dependent kinase 5 (Cdk5) at Ser273 in PPARγ.
The latter prevent the expression of target genes involved in lipid and glucose homeostasis, and seem
to play a key role in the insulin–sensitizing effect of PPARγ agonists [18,31,89,90]. TZDs have been
shown to inhibit the Cdk5-mediated phosphorylation of PPARγ in adipose tissue and the same is
true with PPARγ ligands with poor agonistic activity but with potent antidiabetic effects in vivo.
The inhibition of Ser273 phosphorylation by ligands does not seem to depend on the degree of classical
agonist action [13,31,89,90]. The antidiabetic effect of full and partial agonists of PPARγ may therefore
in part be explained by the inhibition of PPARγ phosphorylation. However, the classical agonist
action seem to explain the side effects of full agonists. Thus, an effective PPARγ agonist should have
a weak transactivation activity, but high phosphorylation inhibitory activity of PPARγ [13,18,89,90].
Testing for inhibition of Cdk5-mediated PPARγ phosphorylation is not a part of the screening platform
but should be considered as an additional test aiming at elucidating the overall activity profile of
promising antidiabetic natural products that act as partial PPARγ agonists.
6.1. In Silico Docking for Investigation of Partial PPARγ Agonism of Natural Products
Knowing the exact chemical structure of a PPARγ agonist, it is possible to perform in silico
docking of the agonist in the PPARγ LBD and determine whether the binding mode of the ligand
resembles that of a full or a partial PPARγ agonist. Kotowska et al. [47] and El-Houri et al. [48] used
the docking method GOLD version 5.1 and default parameters (GoldScore, 100% search efficiency) to
determine partial PPARγ agonism of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides
and FaOH and FaDOH, respectively (Figures 9 and 10). The active site was determined by selecting
all residues within a radius of 6 Å of the co-crystalized ligand for human PPARγ. After docking, the
compounds were minimized using LigandScout software and the best docking poses for the ligands
were selected by developing a 3D pharmacophore [18,47,48].
In silico docking studies of the dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides into
the PPARγ LBD predicted binding modes to one hydrogen bond with the amino acid Ser342 and
hydrophobic interactions with several amino acids from arms II and III (Figure 9) [47]. In addition, no
hydrogen bond interaction between dodeca-2E,4E,8Z,10E/Z-tetraenoic acid 2-methylbutylamides and
amino acids from arm I was predicted. Thus, the docking mode of dodeca-2E,4E,8Z,10E/Z-tetraenoic
acid 2-methylbutylamides into the PPARγ LBD combined with the weak activation of PPARγ as well
as the results of the competitive PPARγ binding assay, suggests that these compounds are acting as
PPARγ partial agonists.
In silico docking of FaOH and FaDOH into the PPARγ LBD revealed that the different
PPARγ activities of these polyacetylenes to some extent can be explained by their binding modes to
the PPARγ LBD. The best docking pose for FaOH established a hydrogen bond between the amino
acid Ser342 and the hydroxyl group at C-3. For FaDOH the best docking pose predicted a hydrogen
bond between the hydroxyl group at C-3 and the amino acid Leu228 and between the hydroxyl group
at C-8 and Ser342.
In addition, in silico docking established several hydrophobic interactions between the LBD and
FaOH and FaDOH, respectively (Figure 10) [48]. The extra hydrogen bond of FaDOH to the LBD
of PPARγ compared to FaOH may explain why FaDOH is a more effective activator of PPARγ than
FaOH. The predicted binding modes of FaOH and FaDOH with arms II and III, clearly indicates that
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these natural products are partial PPARγ agonists. For FaDOH this is in accordance with previous
investigations using another docking model [13,72].
Figure 9. The predicted binding modes of dodeca-2E,4E,8Z,10E-tetraenoic acid 2-methylbutylamide
to the PPARγ LBD illustrated in a 2D-model (top) and 3D-model (bottom). The chemical
interaction pattern is the same for dodeca-2E,4E,8Z,10Z-tetraenoic acid 2-methylbutylamide. Binding
modes to the LBD in the 2D-model are color-coded: red dashed arrow = hydrogen bond;
blue line = hydrophobic interactions.
Figure 10. The predicted binding modes of FaOH and FaDOH to the PPARγ LBD illustrated in a
2D-model (top) and a 3D-model (bottom). Binding modes to the LBD in the 2D-model are color-coded:
red dashed arrow = hydrogen bond; blue line = hydrophobic interactions.
The PPARγ activating properties of alkamides and polyacetylenes as well as closely related
endogenous and/or dietary PPARγ ligands appears to depend on the length of their aliphatic chain
and functional groups, and thus on their interactions with the LBD [27,47]. However, the large cavity of
the PPARγ LBD, and thus the broad specificity of this receptor, makes the prediction of PPARγ activity
of small molecules difficult. Therefore, in silico docking can only be considered as an important tool to
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confirm that a natural product may act as a partial PPARγ agonist and to give a reasonable explanation
for its partial PPARγ agonism.
7. Conclusions
The screening platform presented in this review has been developed based on our experience
with bioassay-guided fractionation of plant extracts for the isolation and characterization of promising
antidiabetic compounds. The screening platform has shown to be rather efficient in isolating
potential antidiabetic partial PPARγ agonists from complex plant extracts as demonstrated by
the isolation of potential antidiabetic alkamides and polyacetylenes from the roots of E. purpurea
and carrots, respectively. A bioassay-guided fractionation approach of the lipophilic extract of
the roots of E. purpurea using an insulin-dependent GU bioassay resulted in the isolation of an
inseparable mixture of two new C12-isomeric alkamides demonstrating promising antidiabetic effects
by significantly enhancing basal GU and insulin-dependent GU in adipocytes and exhibiting the
characteristics of PPARγ partial agonists. Similarly, the screening platform has been used to identify
the potential antidiabetic polyacetylenes FaOH and FaDOH from the lipophilic extracts of carrots.
The polyacetylenes enhanced GU in adipocytes in a dose-dependent manner and displayed also the
characteristics of PPARγ partial agonists. FaOH inhibited adipocyte differentiation as evident by gene
expression studies and Oil Red O staining, whereas this was not the case for FaDOH. This indicates
that these polyacetylenes may have distinct mechanisms of action. In silico docking experiments
with FaOH and FaDOH, respectively, into the PPARγ LBD revealed that these polyacetylenes have
different binding modes that may result in the recruitment of different beneficial PPARγ coactivators
and thus confirm that FaOH and FaDOH may have distinct mechanisms of action. Coactovator
recruitment is not an essential part of the screening platform but are important bioassays in order to
provide further information on the mechanisms of action of the antidiabetic effects of purified partial
PPARγ agonists. In addition, some partial PPARγ agonists may function as dual PPAR agonists or
pan PPAR agonists and/or inhibit phosphyrolation of PPARγ, which are all important factors for
elucidating the mechanisms of action of partial PPARγ agonists and hence evaluate their antidiabetic
potential and possible side effects, before entering preclinical trials.
In conclusion, the screening platform presented in this review represents an effective method for
the identification of potential antidiabetic partial PPARγ agonists from complex extracts that can turn
out to be lead compounds for developing drugs for the prevention and/or treatment of T2D.
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